1	Efficacy of acupuncture for chronic prostatitis/chronic pelvic pain
2	syndromes on quality of life: study protocol for a randomized, sham
3	acupuncture-controlled trial
4	Yu-Long Ding ^{1*} , Huai-Yu Wang ¹ , Yuan Ji ^{1,2} , Shuo Zhang ¹ , Peng-Fei
5	Yuan ¹ , Hong-Chao Zhao ¹ , Yan Guo ¹ , Xiao-Di Xie ¹
6	¹ Beijing Fengtai Hospital of Integrated Traditional and Western
7	Medicine
8	² Beijing University of Chinese Medicine Third Affiliated Hospital
9	
10	*Correspondence: Yu-Long Ding, MD, Department of Acupuncture and
11	Neurology, Beijing Fengtai Hospital of Integrated Traditional and
12	Western Medicine, Beijing, China, No.60 Sanlijia, Dongshan Slope,
13	Changxindian, Fengtai District, Beijing 100072, China. Emial:
14	princezzbmw@163.com
15	
16	Short title: Acupuncture for QoL of CP/CPPS
17	Numbers of references:23
18	Tables:2
19	Figures:1
20	Total words:4606 words

21 Abstract

Background: Chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) is a 22 common heterogeneous disease that seriously impacts patients' quality of life (QoL). 23 24 Acupuncture therapy has been widely used in China for various urinary diseases and symptoms, including chronic prostatitis. The results of several randomized controlled 25 studies from different countries support that acupuncture can relieve the symptoms of 26 27 CP/CPPS. Still, most randomized controlled trial (RCT) trials focus on symptom relief in patients, and the evidence on improving the QoL is insufficient. This study 28 aims to assess the near-term and long-term efficacy of acupuncture in improving QoL 29 30 in patients with CP/CPPS. 31 Methods/Design:

32 This is a double-arm, parallel, participant-blinded RCT. 70 male CP/CPPS subjects

aged 18-50 will be randomly allocated to either the acupuncture group or the sham

34 acupuncture group. Participants will receive acupuncture or sham acupuncture

treatment thrice a week over eight weeks for 24 sessions. The primary outcome will

36 be the change in the total score of QoL compared with the baseline after eight weeks

of treatment and 24 weeks of follow-up. The expectancy of acupuncture, blinding, and

38 safety will also be assessed. A two-sided test will perform all statistical analyses, and

a *p*-value of less than 0.05 will be considered statically significant.

40 **Discussion**: This study aims to provide quantitative clinical evidence of acupuncture

41 effectiveness and safety in improving the QoL in patients with CP/CPPS.

42 Clinical Trial Registration: This trial is registered at chictr.org.cn (Identifier:

43 ChiCTR2100051115)

44 Keywords: acupuncture; CP/CPPS; QoL; protocol; RCT

45 Introduction

46 CP/CPPS is a common genitourinary disease in the adult male population. This

47 disease is mainly manifested by repeated and long-term pain, discomfort in the pelvic

48 area, and different degrees of lower urinary tract symptoms. A substantial number of

49 patients experience mental symptoms and abnormalities in sexual function, which

50 adversely affect clinical efficacy and rehabilitation^[1].

According to the National Institutes of Health (NIH) classification, chronic CP/CPPS 51 belongs to type III prostatitis. Type III prostatitis includes two subtypes: type III A 52 (inflammatory CPPS) and type III B (non-inflammatory CP/CPPS). With the 53 deepening of the study of CP/CPPS, experts realize that the etiology of CP/CPPS is 54 complex, with different mechanisms, different clinical manifestations, different 55 56 disease processes, and different responses to treatment of heterogeneous clinical syndrome, so curing CP/CPPS is not a realistic goal. At present, the clinical drug 57 treatment of the disease is mainly symptomatic treatment, such as antibiotic treatment, 58 59 beta-blockers, nonsteroidal anti-inflammatory drugs, anxiety medication and 60 antidepressants, and botanical agents are widely used in clinical practice. However, 61 the effect of the above treatment measures is not ideal, and there are specific adverse reactions and long-term use of patients with poor compliance. 62 In recent years, more and more attention has been paid to the QoL of patients. QoL is 63 64 patients' sense of approval and satisfaction compared to their expected or reachable 65 functional state. It is a subjective feeling. In the clinical studies of different diseases, it 66 is found that doctors often pay more attention to the significance of changes in objective indicators, and the understanding of the subjective state of patients is often 67 inaccurate or not completely accurate, but the most important thing for patients is 68 69 their subjective QoL. For example, the Atrial Fibrillation (AF) load, as a measurable 70 and objective indicator, is highly valued by clinicians. However, whether it has a 71 special significance for the patients is still being determined^[2]. Clinical observation 72 shows that some patients with persistent AF do not have any symptoms, while some 73 patients with paroxysmal AF may experience severe symptoms such as dyspnea 74 during the attack. The use of less toxic treatments than existing standard therapies to improve the QoL of patients with advanced non-small cell lung cancer (NSCLC) has 75 not achieved the expected effect^[3]. Therefore, from the point of view of patients and 76 77 caregivers, it is more important to accurately assess the impact of the disease on the

78 overall health of patients rather than just focusing on objective indicators. 79 Acupuncture has been widely used in many urinary diseases and symptoms in China, 80 including chronic prostatitis^[4-6]. Several randomized controlled trials from different countries show that acupuncture can relieve the symptoms of CP/CPPS^[5-8]. The results 81 of a multicenter large sample RCT trial published in ANN INTERN MED in 2021 82 83 showed that 8-week acupuncture could effectively improve the symptoms of patients 84 with moderate and severe chronic prostatitis / chronic pelvic floor pain syndrome (CP/CPPS). The clinical effect lasted at least half a year without involving patients' 85 OoL^[9]. Most of the available data focus on symptom improvement in CP/CPPS 86 patients, as controlling symptoms is an ideal way and way to improve QoL. However, 87 88 symptoms and QoL cannot be equated, and the scores of QoL in patients with CP/CPPS may change in different dimensions because of their various symptoms. The 89 evidence is insufficient on the efficacy of acupuncture studies in improving the QoL 90 in patients with CP/CPPS. Currently, we regard acupuncture as an effective TCM 91 92 rehabilitation method for treating CP/CPPS. Therefore, we assume that true acupuncture will have better clinical efficacy than sham acupuncture in improving 93 94 QoL, symptom score, and long-term effectiveness.

95 Methods and Analysis

96 Study Design

97 A double-arm, parallel, participant-blinded randomized controlled trial (RCT) will be conducted at the Beijing Fengtai Hospital of Integrated Traditional Chinese and 98 99 Western Medicine, a level A tertiary teaching hospital. The protocol has been 100 registered in the China Clinical trial Registry (Project No. ChiCTR2100051115), and 101 the study protocol has been approved by the Ethics Committee of Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine (Project No.: 19-102 103 Scientific Research-12-20). A total of 70 patients will be recruited, and all patients 104 enrolled in the trial will voluntarily sign the informed consent form. Patients were 105 randomly assigned to either the acupuncture treatment group (Acu Group) or the sham

⁴

106 needle control group (Sham Group). Assessors will evaluate efficacy indicators before

107 treatment, eight weeks after treatment, and 24 weeks after completion of therapy.

- 108 Beijing University of Chinese Medicine (BUCM) will be responsible for data
- 109 management and statistics. The flowchart of the trial is shown in Figure 1, and Table
- 110 2 shows the schedule of the measurements.
- 111

Figure 1. Flow chart of the trial. DMC, the data monitoring committee

112 **Participant Recruitment**

113 This project is expected to recruit 70 male patients between January and December

114 2022. A urologist will screen CP/CPPS patients through medical history, physical

examination, and laboratory examination. All participants will have to meet the

116 CP/CPPS diagnostic criteria agreed upon by the NIH: the discomfort or pain of the

117 pelvic area will last for at least three months in the past six months. The 2-glass test

and other examinations, including prostatic fluid cultures, prostate-specific antigen

119 evaluation, urine flow rate, and residual urine examination, will collect the prostatic

120 fluid/urine specimen microbiology. Patients aged 18 to 50 years with National

121 Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score ≥ 15

are eligible to participate. Participants will be screened if they agree to sign an

123 informed consent form. Research assistants will conduct recruitment.

Inclusion Criteria

125 The criteria for inclusion in this study are the following: (1) the clinical manifestations were repeated and persistent prostate pain accompanied by abnormal urination and 126 mental and neurological symptoms in the last six months, and no infection or other 127 128 obvious pathological conditions were confirmed. The symptoms lasted for more than three months. The main clinical manifestations are a pain in the surrounding tissue 129 130 radiated by the prostate as the center. Joint pain, distension, or discomfort in the scrotum, testis, lower abdomen, perineum, lumbosacral, medial thigh, etc.: abnormal 131 urination is characterized by frequent urination, urgency, pain, burning of the urethra, 132 residual urine, or white discharge from the urethra when getting up in the morning, 133

end of urine or defecation. Mental and neurological symptoms include dizziness and

tinnitus, insomnia and dreaming, anxiety and depression, or even sexual dysfunction
such as impotence and premature ejaculation. (2) aged 18 to 50 years; (3) NIH-CPSI

- total score \geq 15; (4) Voluntarily participate in this experiment and sign the informed
- 138 consent form.

139 Exclusion Criteria

Potential participants will be excluded for any of the following: (1) bladder outlet 140 obstruction, bladder hyperactivity, neurogenic bladder, interstitial cystitis, cystitis 141 142 glandularis, sexually transmitted diseases, cancer in situ and other bladder tumors, prostate cancer, urinary tract infection, other types of prostatitis, etc.; (2) residual 143 urine > 100 ml by transabdominal ultrasonography, the maximum urinary flow rate is 144 <15ml/s; (3) use of drugs to relieve the symptoms of CP/CPPS or receiving non-drug 145 146 therapy for CP/CPPS (acupuncture, biofeedback, etc.) during the previous 1 month, and taking drugs that affect the function of the lower urinary tract; (4) Symptomatic 147 urinary tract infection and urinary system organic diseases; (5) Diseases affecting the 148 function of lower urethra, such as multiple sclerosis, Alzheimer's disease, Parkinson's 149 150 disease, spinal cord injury, cauda equina injury, stroke and multiple system atrophy, etc.; (6) Patients with severe heart, lung, brain, liver, kidney and hematopoietic system 151 diseases, mental illness and apparent cognitive impairment. 152

153 Randomization and Blinding

154 A randomized controlled design was adopted in this study. The random number of this study will be generated and sealed by the network department of our hospital and 155 will be kept by the managers of the research group who do not participate in the 156 project. Depending on the information received from the envelope, consecutive 157 158 participants will be randomly assigned 1:1 to either the Acu group or the sham group. The acupuncturist will be given to perform acupuncture treatment for two groups. The 159 study coordinator will not participate in the assessment or treatment. They will inform 160 patients that they may receive either "the less painful acupuncture arm specifically 161 developed for this study" (sham group) or the "traditional Chinese acupuncture arm" 162 (Acu group). Efficacy assessors, acupuncture operators, and statisticians will be 163

separated. Non-acupoint micro-acupuncture will allow the subjects to be blinded and 164 evaluated in a blinded way after the last treatment. 165

Interventions 166

Participants will receive acupuncture or sham acupuncture for 30 minutes in the 167 supine position thrice a week for eight weeks. In addition, each treatment form and 168 evaluation form will be completed and signed by patients and researchers. Two 169 170 acupuncturists each will be responsible for the two groups. Before treatment, participants will be told they would receive traditional acupuncture with relatively 171 deep acupuncture or minimal acupuncture with relatively shallow acupuncture at non-172 173 acupoints. Participants will receive treatment according to appointments to maintain blindness and avoid communication. The acupoints used are located in the 174 175 lumbosacral region and the back of the tibia, which is difficult for participants to see when they lie prone. Participants may feel the needle penetrate the skin, but they are 176 usually unable to judge the depth of the needle. To test the success of the blind 177 178 method, within five minutes of two treatments in the eighth week, participants were 179 asked if they had received traditional acupuncture in the previous weeks (yes, no, or 180 unclear). The use of drugs or other therapies for CP/CPPS will be avoided during the study 181

unless participants' symptoms are intolerable. Other medicines for CP/CPPS 182 symptoms, such as α blockers, are not allowed in principle: all out-of-regimen

treatments should be carefully documented in the Case Report Form (CRF). Any 184

drugs affecting lower urinary tract function should also be recorded and statistically 185

186 analyzed. Participants will receive instructions on health care education and lifestyle

187 changes, including exercise, weight loss, smoking, etc.

Acupuncture Group 188

183

The development of the acupuncture protocol was based on the consensus of 189

190 acupuncturists from Guang' anmen Hospital. The locations of the acupoints (Table 1)

191 follow the World Health Organization (WHO) standard acupuncture point

192	locations ^[10] . Bilateral Shenshu (BL23), Zhongliao (BL33), Huiyang (BL35), and
193	Sanyinjiao (SP6) ^[9] will be inserted using stainless steel disposable aseptic
194	acupuncture needles (sizes 0.30×75 and 0.30×40 mm). Bilateral BL33 will be inserted
195	to a depth of 50 to 60 mm with a 30° to 45° angle in an inferomedial direction using
196	needles (0.30 mm in diameter, 75 mm in length). Bilateral BL35 will be inserted to a
197	depth of 50 to 60 mm with a slightly superolateral direction using needles (0.30 mm
198	in diameter, 75 mm in length). Bilateral BL23 and SP6 will be inserted vertically to a
199	depth of 25 to 30 mm using needles (0.30 mm in diameter, 40 mm in length).
200	Manipulation of the needles by lifting and thrusting combined with twirling and
201	rotating evenly will be performed until deqi occurs, a sensation of soreness,
202	numbness, heaviness, and ache. Manipulations will be applied every 10 minutes, and
203	each session will last for 30 minutes.

204

Table 1. Locations of the selected acupoints for treating CP/CPPS

Acupoints	Real acupuncture location	Sham acupuncture location	
Zhongliao (BL33)	In the sacral region, the third posterior sacral foramen		
Huiyang (BL35)	In the buttock region, 0.5 cun lateral to the extremity of the coccyx	Inserted at non-acupuncture	
Shenshu (BL23)	In the lumbar region, at the same level as the inferior border of the spinous process of the second lumbar vertebra (L2), 1.5 proportional bone (skeletal) cun lateral to the posterior median line.	corresponding acupoints (15 mm to BL23, BL33, and BL35; 10 mm to SP6) with depths of 2-3 mm without manipulation	
Sanyinjiao (SP6)	On the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus		

205 Localization of these acupoints is based on the WHO Standard Acupuncture Point Locations in the Western Pacific

206 Region.

Sham Acupuncture Group 207

Bilateral sham BL23, BL33, BL35 (15 mm to BL23, BL33, and BL35), and SP6 (10 208

mm to SP6) will be inserted by needles (size 0.2×25 mm) to a depth of 2 to 3 mm 209

210 without manipulation and causing the feeling of *Deqi*.

211 Outcome Measures

212 The Primary Outcome

213 Main outcome measures: after eight weeks of treatment and 24 weeks of follow-up,

214 we will use the Chinese version of SF-36 (The MOS item short-form health survey) to

evaluate the short-term effect of acupuncture for eight weeks to improve the QoL of

216 patients with CP/CPPS, followed by 24 weeks of follow-up.

217 Secondary Outcomes

218 The secondary outcomes of this study include (a) a change in the International

219 Prostate Symptom Score (IPSS). IPSS is a valid, reliable, and sensitive measure for

220 patients with lower urinary tract symptoms (LUTS); it is widely used in clinical

221 practice and research to determine the severity of LUTS, including incomplete

bladder emptying, frequency of urination, intermittency, urgency, weak urine stream,

straining and nocturia^[11,12]; (b) change in the NIH-CPSI total score, the total score of

the Chinese version NIH-CPSI. As a validated, self-reported questionnaire, NIH-CPSI

is widely used to assess CP/CPPS symptoms^[13,14]; (c) change in the NIH-CPSI

subscales, including pain, urinary symptoms, and QoL impact. NIH-CPSI consists of

9 items divided into three discrete domains: pain (0-21 points), urinary symptoms (0-

10 points), and QoL (0-12 points), with a total score of 0-43 points (a higher score

229 indicates worse symptoms). A decline of at least 6 points in NIH-CPSI has been

identified as the minimal clinically significant difference (MCID)^[15]; (d) changes in

the visual analog scale (VAS) of pelvic floor pain. Secondary Outcomes will be

assessed at the end of the 8^{th} and 24^{th} compared with baseline and the safety of

acupuncture.

Figure 2. Study schedule showing the time points for enrollment and assessment
 ×, required; SF-36, The MOS item short-form health survey; IPSS, International Prostate Symptom Score; NIH CPSI, The National Institute of Health Chronic Prostatitis Symptom Index; VAS, Visual analog scale.

237 Incidence of Adverse Events

- 238 Patients will be asked to report any acupuncture-related adverse events (AEs)
- voluntarily. The researchers will record and evaluate. Acupuncture-related adverse
- 240 reactions include bleeding, local infection, soreness, sweating, and so on.

241 Sample Size Estimation

Based on the previous pre-experimental study with a sample size of 20 people, 72% of

the patients in the acupuncture group had a total NIH-CPSI score of 6 points or lower

than the baseline at the 8th week of treatment, and 36% of the patients were sham

acupuncture. Take α =0.05, β =0.1, Power=0.9. 70 samples will be needed for 35 cases

in each group.

247 Data Collection and Management

Collect data clearly and entirely in the CRF. All raw data sources will be retained,

249 including CRFs, informed consent, and inspection results. An independent data

administrator is responsible for completing the customer report format and will be

required to double-enter the data for proofreading. All trial-related data will be kept

252 for at least five years after publication. The reader can get the raw data by contacting

the corresponding author. Patient information, including name, age, and phone

254 number, will remain anonymous. An independent data and safety monitor board

- 255 (DSMB) was established to ensure the integrity of the study data. The DSMB will
- 256 review progress and decide whether premature closure is needed. Beijing Fengtai
- 257 Hospital of Integrated Traditional and Western Medicine will designate at least three
- 258 non-treatment practitioners to supervise the quality of the research

Quality control

260 All practitioners, including acupuncturists, research assistants, and statisticians, will

be required to attend training to ensure the quality of this trial. The acupuncture

262 operator must have the acupuncture doctor qualification certificate and independently

- 263 undertake the clinical treatment for more than two years. Interventions will be carried
- 264 out based on strict compliance with standardized operating procedures.

265 Statistical Analysis

Statistical analysis will be based on the principle of intention to treat, and third-party 266 statisticians are unaware of group allocation and intervention procedures. The missing 267 268 data will be estimated using the last observation carry-over method. Normally distributed numerical data are presented as mean \pm standard deviation, and 269 non-normally distributed data are presented as medians with confidence intervals of 270 271 95%. For normally distributed data, repeated measures analysis of variance (ANOVA) was used for within-group and between-group comparisons to assess changes in 272 continuous variables at different time points before and after the intervention; for non-273 274 normally distributed data, nonparametric tests were used to compare within groups and between groups. All data were analyzed using SPSS 22.0. All hypothesis tests 275 276 were two-sided, and p values < 0.05 were considered statistically significant.

277 **Discussion**

The incidence of CP/CPPS in men is high, and the cure rate is low. CP/CPPS is often 278 279 associated with lower urinary tract dysfunction and negative emotion, cognition, and/or sexual dysfunction^[16]. It seriously affects the QoL and mental health of the 280 patients. In recent years, the pathogenesis of CP/CPPS has been the research focus. 281 Many factors, such as urinary reflux^[17], pathogen infection^[18], inflammation, and 282 283 oxidative stress^[19,20], may be involved in the pathogenesis of CP/CPPS. However, the 284 existing treatment methods are not ideal because of their complicated clinical manifestations and lingering disease^[21]. Some patients with prostate inflammation 285 after the disappearance of pain still exist for a long time. Therefore, seeking an 286 effective and safe non-drug therapy to reduce the urinary tract symptoms associated 287 with patients, relieve pain, improve the QoL of patients with CP/CPPS, and reduce the 288 side effects and medical costs of drug therapy is the key to treating CP/CPPS. 289 Acupuncture has long been a non-pharmacological approach to pain treatment, with 290 291 lasting effects of more than 12 months. A growing number of trials have shown that

acupuncture may reduce symptoms compared with standard medical treatments^[22]. In

a Cochrane review of 20 non-pharmacological interventions evaluated for

294 CP/CPPS^[23], only acupuncture and extracorporeal shock wave therapy likely result in 295 symptom relief with reasonable safety. The study group found that 440 patients with 296 CP/CPPS were randomly divided into an acupuncture group and a sham-acupuncture 297 group. The two groups were treated with acupuncture and simulated acupuncture for 298 eight weeks and 20 times, respectively. The results showed that the improvement of CP/CPPS symptoms in the acupuncture group was significantly better than in the 299 300 control group. The difference between the two groups was clinically significant. The 301 therapeutic effect could be maintained for half a year after stopping the treatment, and 302 adverse events seldom occurred during the treatment. This study confirmed the long-303 term efficacy and safety of acupuncture in the treatment of CP/CPPS with high-304 quality clinical evidence.

Compared with the depth of the study on the pathogenesis of CP/CPPS by mainstream 305 306 medicine in recent years, the study on the mechanism of the treatment of CP/CPPS by 307 acupuncture and moxibustion is still in the initial stage. CP/CPPS is a kind of 308 symptom-dependent disease. The most basic aim of treatment is to improve the 309 symptoms. The current research results can not clarify the pathogenesis and pathway of the disease, so it is challenging to explore accurate treatment targets on this basis. 310 311 In recent years, with the continuous innovation of equipment and technology, neural 312 regulation has been increasingly used in treating CP/CPPS. Acupuncture therapy can improve the symptoms by stimulating peripheral nerves, one of the modern nerve 313 314 regulation models. For example, Zhongliao (BL33) is at the beginning of the gluteus 315 maximus muscle, when the posterior branch of the lateral iliac artery and vein, and the 316 point is at the beginning of the gluteus maximus muscle, the posterior branches of the 317 second sacral nerve (S2) and the third sacral nerve (S3) pass through. The 318 acupuncture sensation mostly stays in the local area when the superficial layer is 319 punctured, which has a definite therapeutic effect on most of the local lumbosacral 320 lesions. It will produce the needle sensation radiating to the anterior vulva, lower

abdomen, and pelvic cavity, which has a better effect on the reproductive system,
urinary system diseases, and regulating the function of the bladder when the
acupuncture reaches a certain depth. Sanyinjiao (PC6) is a distal acupoint of the
limbs; deep needling can stimulate the main trunk of the tibial nerve, which is a

branch of the sciatic nerve and contains L4-S3 nerve fibers, stimulation of the tibial

- 326 nerve can effectively stimulate the approach targeting the sacral plexus to improve the
- 327 voiding symptoms in patients with CP/CPPS.
- 328 CP/CPPS is often associated with negative emotions, cognition, and/or sexual
- 329 dysfunction and is a typical psychosomatic disorder. Acupuncture treatment can
- regulate peripheral nerves, inhibit pain signals from the pain conduction pathway to
- 331 produce an analgesic effect, and improve pain threshold perception by improving
- 332 pain-related emotion. But whether acupuncture can improve the QoL of patients with
- 333 CP/CPPS is still uncertain. In this trial, we will use sham acupuncture to assess
- 334 whether acupuncture improves the QoL and effectively relieves both short-and long-
- term symptoms in patients with CP/CPPS. With a 24-week follow-up of patients and
- 336 strict quality control, our study will provide substantial evidence as to whether
- acupuncture can improve QoL in patients with CP/CPPS.

338 **Conclusions:**

The clinician not only needs to evaluate the disease comprehensively and consider the

340 objective physiological indexes but also needs to understand the influence of the

- 341 disease on the patient's subjective feelings and functional status, as its physical,
- 342 psychological, and social life and other aspects of the impact of patients to guide the
- 343 rehabilitation and health decision-making. The current Randomized controlled trial
- 344 protocols aim to investigate the efficacy and safety of acupuncture in treating patients
- 345 with CP/CPPS. This trial is the first in the acupuncture field to use Randomized
- 346 controlled trial QoL as a primary outcome measure.

347 Ethics Statement

348 The Ethics Committee of the Beijing Fengtai District Integrated Chinese and Western

349 medicine hospital reviewed and approved these studies involving human participants.

350 Patients/participants provided their written informed consent to participate in the

351 study.

352 Author Contributions

353 The manuscript's content is accurate and represents the authors' work/opinions, not

those of the sponsoring agent(s). Yu-long Ding put forward the idea of performing

- this review. Yu-long Ding wrote the initial paper. Yu-long Ding, Huai-Yu Wang, and
- 356 Yuan-Ji revised and edited the manuscript. Shuo Zhang and Peng-Fei Yue drew the
- 357 picture. Hong-Chao Zhao, Yan Guo, and Xiao-Di Xie summarized the tables. All
- 358 authors have approved the submitted version. The authors declare that they have no
- 359 conflict of interest.

360 Funding

361 This work was supported by Fengtai District Health System Research Project (No.

362 2019-90)

363 Conflict of Interest

- 364 The authors declare that the research was conducted without any commercial or
- 365 financial relationships that could be construed as a potential conflict of interest.

366 Acknowledgments

- 367 We want to thank professors Zhi-Shun Liu, Yu-Ying Cai, and Hong Zhao from Guang
- 368 'anmen Hospital of China Academy of Chinese Medical Sciences for their guidance in
- the design and implementation of the project.

370 Abbreviations

- 371 CP/CPPS chronic prostatitis/chronic pelvic pain syndromes
- 372 QoL quality of life
- 373 RCT randomized controlled trial
- 374 NIH National Institutes of Health
- 375 AF atrial fibrillation
- 376 NSCLC non-small cell lung cancer
- 377 Acu Group acupuncture treatment group

- 378 Sham Group sham needle control group
- 379 BUCM Beijing University of Chinese Medicine
- 380 NIH-CPSI National Institutes of Health Chronic Prostatitis Symptom Index
- 381 CRF case report form
- 382 WHO World Health Organization
- 383 BL Bladder Meridian
- 384 SP Spleen Meridian
- 385 SF-36 the MOS item short-form health survey
- 386 IPSS international prostate symptom score
- 387 LUTS lower urinary tract symptoms
- 388 MCID minimal clinically important difference
- 389 VAS visual analog scale
- 390 AEs adverse events
- 391 DSMB the data and safety monitor board
- 392 ANOVA analysis of variance
- 393

394 **References**

- 395 1 Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis[J].
- **396** JAMA, 1999, 282(3):236-237.
- 397 2 Dorian P, Brijmohan HBSc A. The Role of Quality of Life Indices in Patient-Centred
- 398 Management of Arrhythmia[J]. Can J Cardiol, 2020, 36(7):1022-1031.
- **399 3** Di Maio M. Quality of life: an important element of treatment value[J]. Lancet Oncol, 2017,
- 400 18(12):1557-1558.
- 401 4 Wang Y, Liu B, Yu J, et al. Electroacupuncture for moderate and severe benign prostatic
- 402 hyperplasia: a randomized controlled trial[J]. Plos One, 2013, 8(4): e59449.
- 403 5 Lee S W H, Men L L, Yuen K H, et al. Acupuncture versus Sham Acupuncture for Chronic
- 404 Prostatitis/Chronic Pelvic Pain[J]. American Journal of Medicine, 2008, 121(1):1-7.
- 405 6 Sahin S, Bicer M, Eren G A, et al. Acupuncture relieves symptoms in chronic prostatitis/chronic
- 406 pelvic pain syndrome: a randomized, sham-controlled trial[J]. Prostate Cancer & Prostatic

- 407 Diseases, 2015, 18(3):249-254.
- 408 7 Lee S H, Lee B C. Use of Acupuncture as a Treatment Method for Chronic Prostatitis/Chronic
- 409 Pelvic Pain Syndromes[J]. Current Urology Reports, 2011, 12(4):288-296.
- 410 8 Küçük E V, Suçeken F Y, Bindayı A, et al. Effectiveness of Acupuncture on Chronic
- 411 Prostatitis/Chronic Pelvic Pain Syndrome Category IIIB Patients: A Prospective, Randomized,
- 412 Nonblinded, Clinical Trial[J]. Urology, 2015, 85(3):636-640.
- 413 9 Sun Y, Liu Y, Liu B, et al. Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain
- 414 Syndrome: A Randomized Trial[J]. Ann Intern Med, 2021, 174(10):1357-1366.
- 415 10 World Health Organization, WHO Standard Acupuncture Point Locations in the Western
- 416 Pacific Region, WHO Western Pacific Region, Geneva, Switzerland, 2008.
- 417 11 Edmond PH, Cindy LK, Weng YC. Validation of the international prostate symptom score in
- 418 Chinese males and females with lower urinary tract[J]. Health Qual Life Outcomes, 2014, 12:1-9.
- 419 12 Szeto PS. Application of the Chinese version of the international prostate symptom score for
- 420 the management of lower urinary tract symptoms in a primary health care setting[J]. Hong Kong
- 421 Med J, 2008,14(6):458-464.
- 422 13 Hong K, Xu QQ, Jiang H, et al. Chronic Prostatitis Symptom Index of Chinese[J]. Zhonghua
- 423 Nan Ke Xue, 2002,8(1):38-41.
- 424 14 Litwin MS. A review of the development and validation of the National Institutes of Health
- 425 Chronic Prostatitis Symptom Index[J]. Urology, 2002, 60(6 Suppl):14-18.
- 426 15 Propert KJ, Litwin MS, Wang Y, et al. Responsiveness of the National Institutes of Health
- 427 Chronic Prostatitis Symptom Index (NIH-CPSI) [J]. Qual Life Res, 2006, 15(2):299-305.
- 428 16 Fall M, Baranowski AP, Elneil S, et al. EAU guidelines on chronic pelvic pain[J]. European
- 429 Urology, 2010, 57(1): 35-48.
- 430 17 Persson BE, Ronquist G. Evidence for a mechanistic association between nonbacterial
- 431 prostatitis and levels of urate and creatinine in expressed prostatic secretion[J]. J Urol, 1996,
 432 155(3):958-960.
- 433 18 Wu Y, Jiang H, Tan M, et al. Screening for chronic prostatitis pathogens using high-throughput
- 434 next-generation sequencing[J]. Prostate, 2020, 80(7):577-587.
- 435 19 Zhang M, Liu Y, Chen J, et al. Single-cell multi-omics analysis presents the landscape of
- 436 peripheral blood T-cell subsets in human chronic prostatitis/chronic pelvic pain syndrome[J]. J
- 437 Cell Mol Med, 2020, 24(23):14099-14109.

- 438 20 Hua X, Ge S, Zhang M, et al. Pathogenic roles of CXCL10 in experimental autoimmune
- prostatitis by modulating macrophage chemotaxis and cytokine secretion[J]. Front Immunol, 2021,
- **440** 12:706027.
- 441 21 Yu XJ, Gao QH. Guidelines for Multidisciplinary Diagnosis and Treatment of Chronic
- 442 Prostatitis with Integrated Traditional Chinese and Western Medicine[J]. National Journal of
- 443 Andrology, 2020, 26(04):369-376.
- 444 22 Franco JVA, Turk T, Jung JH, et al. Non-pharmacological interventions for treating chronic
- 445 prostatitis/chronic pelvic pain syndrome[J]. BJU Int, 2019, 124(2):197-208.
- 446 23 Franco JV, Turk T, Jung JH, et al. Non-pharmacological interventions for treating chronic
- 447 prostatitis/chronic pelvic pain syndrome[J]. Cochrane Database Syst Rev, 2018, 5(5): CD012551.



Figure 1

medRxiv pretrin the set e / co b of the //co preprint (which was not certified b) peer re	22.12.23.222388823 this version posted view) is the outhor/funder, who has gra percetuity.	December 27, 2023. The copyright hont the medRxiv a license to display the	order for this 8 weeks	32 weeks
	CC-BY 4.0 Internation	nal license		
				V
				~

Figure 2